136 related articles for article (PubMed ID: 25032195)
1. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate.
Gupta V; Garg M; Chaudhry M; Singh S; Sen R; Gill M; Sangwaiya A
Prostate Int; 2014; 2(2):90-6. PubMed ID: 25032195
[TBL] [Abstract][Full Text] [Related]
2. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
3. Measurement of cellular proliferation in human prostate by AgNOR, PCNA, and SPF.
Sakr WA; Sarkar FH; Sreepathi P; Drozdowicz S; Crissman JD
Prostate; 1993; 22(2):147-54. PubMed ID: 7681206
[TBL] [Abstract][Full Text] [Related]
4. Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma.
Helpap B; Riede C
Pathol Res Pract; 1995 Jun; 191(5):381-90. PubMed ID: 7479355
[TBL] [Abstract][Full Text] [Related]
5. Nucleolar organizer regions (NOR) in hyperplastic and neoplastic prostate disease.
Deschênes J; Weidner N
Am J Surg Pathol; 1990 Dec; 14(12):1148-55. PubMed ID: 2252105
[TBL] [Abstract][Full Text] [Related]
6. Silver-stained nucleolar organizer regions in the differentiation of prostatic hyperplasia, intraepithelial neoplasia, and adenocarcinoma.
Cheville JC; Clamon GH; Robinson RA
Mod Pathol; 1990 Sep; 3(5):596-8. PubMed ID: 1700418
[TBL] [Abstract][Full Text] [Related]
7. Nucleolar organizer regions and PCNA expression in prostatic cancers.
Kawase N; Shiokawa A; Ota H; Saitoh T; Yoshida H; Kazama K
Pathol Int; 1994 Mar; 44(3):213-22. PubMed ID: 7517763
[TBL] [Abstract][Full Text] [Related]
8. High and low risk prostate carcinoma determined by histologic grade and proliferative activity.
Chiusa L; Galliano D; Formiconi A; Di Primio O; Pich A
Cancer; 1997 May; 79(10):1956-63. PubMed ID: 9149023
[TBL] [Abstract][Full Text] [Related]
9. [Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast].
Di F; Wong NL
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):738-43. PubMed ID: 17374259
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions.
Ahmed ES; Elnour LS; Hassan R; Siddig EE; Chacko ME; Ali ET; Mohamed MA; Munir A; Muneer MS; Mohamed NS; Edris AMM
BMC Res Notes; 2020 Jun; 13(1):295. PubMed ID: 32552908
[TBL] [Abstract][Full Text] [Related]
11. Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness.
Manna AK; Pathak S; Gayen P; Sarkar DK; Kundu AK
Indian J Surg; 2011 Apr; 73(2):101-6. PubMed ID: 22468057
[TBL] [Abstract][Full Text] [Related]
12. Silver-binding nucleolar organizer regions in benign and malignant prostatic lesions.
Pavlakis K; Alivizatos G; Mitropoulos D; Constantinides C; Skopelitou A; Kittas C; Dimopoulos C
Urol Int; 1992; 49(3):137-40. PubMed ID: 1281586
[TBL] [Abstract][Full Text] [Related]
13. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
14. Argyrophilic nuclear organizer regions in nasopharyngeal carcinoma and paraneoplastic epithelia.
Chen M; Lee JC; Lo S; Shen J
Head Neck; 2003 May; 25(5):395-9. PubMed ID: 12692877
[TBL] [Abstract][Full Text] [Related]
15. Nucleolar organiser regions in hyperplastic and neoplastic prostatic tissue.
Hansen AB; Ostergård B
Virchows Arch A Pathol Anat Histopathol; 1990; 417(1):9-13. PubMed ID: 1694333
[TBL] [Abstract][Full Text] [Related]
16. Nucleolar organizer regions as discriminators for the diagnosis of well-differentiated adenocarcinoma of the prostate.
Schned AR
Arch Pathol Lab Med; 1993 Oct; 117(10):1000-4. PubMed ID: 8215819
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of conventional histologic parameters and biologic factors in prostatic needle biopsy are useful to distinguish paramalignant from malignant disease.
Silva LC; Saldiva PH; Ellinger F; Filho BL; Capelozzi VL; Antonangelo L
Pathol Res Pract; 2004; 200(9):599-608. PubMed ID: 15497772
[TBL] [Abstract][Full Text] [Related]
18. Argyrophilic nucleolar organizer regions in atypical adenomatous hyperplasias, prostatic intraepithelial neoplasias and prostatic neoplasms.
Mukherjee J; Misra V; Gupta SC; Gupta AK; Tandon SP
Urol Int; 1997; 58(2):75-9. PubMed ID: 9096266
[TBL] [Abstract][Full Text] [Related]
19. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
